title: The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women.
abstract: OBJECTIVE
  To assess the influence of weight reduction therapy on serum osteoprotegerin (OPG) concentration in obese patients and compare these results with normal-weight controls.
  
  
  METHODS
  Forty-three obese women (BMI, 36.7 +/- 4.1 kg/m2; mean age, 50.1 +/- 4.5 years) were studied. The control group consisted of 19 normal-weight women (BMI, 24.2 +/- 2.1 kg/m2; mean age, 53.8 +/- 5.2 years). In all patients, serum concentrations of OPG, C telopeptide of type I collagen containing the cross-linking site (CTX), osteocalcin, parathormone, 25-(OH)-D3 (vitamin D), and total calcium and phosphorus were assessed before and after a 3-month weight reduction therapy.
  
  
  RESULTS
  In obese subjects, serum concentrations of OPG, 25-(OH)-D3, osteocalcin, total calcium, and phosphorus were significantly lower, and serum concentration of parathormone was significantly higher, before weight reduction therapy in comparison with normal-weight controls. After weight reduction, a significantly higher serum concentration of 25-(OH)-D3 and CTX and significantly lower concentration of OPG were found.
  
  
  CONCLUSIONS
  Serum concentration of OPG was significantly lower in obese patients in comparison with normal-weight controls. Weight reduction therapy resulted in further decrease in OPG serum concentrations. Therefore, OPG cannot be treated as a protective factor from bone loss in obese patients.
authors: Department of Pathophysiology, Medical University of Silesia in Katowice, ul. Medyków 18, 40-752 Katowice, Poland. holomed@poczta.onet.pl
authors: Michał
authors: M
authors: Holecki
authors: Barbara
authors: B
authors: Zahorska-Markiewicz
authors: Joanna
authors: J
authors: Janowska
authors: Teresa
authors: T
authors: Nieszporek
authors: Katarzyna
authors: K
authors: Wojaczyńska-Stanek
authors: Agnieszka
authors: A
authors: Zak-Gołab
authors: Andrzej
authors: A
authors: Wiecek
mesh_terms: D015992:Body Mass Index; D015519:Bone Density / Q000502:physiology; D002112:Calcifediol / Q000097:blood; D002118:Calcium / Q000097:blood; D024042:Collagen Type I / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000378:metabolism; D015675:Osteocalcin / Q000097:blood; D053244:Osteoprotegerin / Q000097:blood* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood; D010455:Peptides / Q000097:blood; D010758:Phosphorus / Q000097:blood; D015431:Weight Loss / Q000502:physiology*; D014965:X-Rays
chemical_list: D024042:Collagen Type I; D053244:Osteoprotegerin; C470125:PTH protein, human; D010281:Parathyroid Hormone; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D010758:Phosphorus; D002112:Calcifediol; D002118:Calcium